Apotex announces launch of the Apotex Global Health Access Fund to promote health equity with $250,000 in annual funding to the Rexdale Community Health Centre
Dec 10, 2024Toronto, Ontario - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced the launch of the Apotex Global Health Access Fund to support programs that promote health equity and address the root causes of health disparities.
Building on Apotex's legacy of giving, including Apotex's global medicine donation program, the Apotex Global Health Access Fund launches with a focus on addressing unequal access to care and low health literacy within communities where there are poor social determinants of health, and where race, economic status, and other factors are barriers to access.
In its inaugural year, the Apotex Global Health Access Fund will focus on funding maternal health programs in Canada, the United States, India, and Mexico with an annual budget of $1 million.
The first recipient of an Apotex Global Health Access Fund grant is the Rexdale Community Health Centre (Rexdale CHC) in Toronto. The Rexdale CHC will receive $250,000 annually over three years to support prenatal and postnatal programs, with a focus on providing much-needed wraparound services to the North Etobicoke community in its clinics and through its recently launched Mobile Health Clinic.
"We are thrilled to launch the Apotex Global Health Access Fund, which underscores our commitment to addressing health inequities and supporting the most vulnerable populations in our key global markets. By focusing on maternal health in our first year, we aim to make a significant impact on the well-being of mothers and their families," said Allan Oberman, President & CEO, Apotex. "The Rexdale Community Health Centre plays a key role in delivering much-needed health services to North Etobicoke residents. As we celebrate Apotex's 50th anniversary, we are honoured to contribute to our local community, and to provide opportunities for our colleagues to do the same."
"We are honoured to be the first recipient of the Apotex Global Health Access Fund. This support will enable us to enhance our maternal health programs and provide critical services to the women in our community. Together, we can work towards a future where every mother has access to the care she needs," said Safia Ahmed, Executive Director of Rexdale Community Health Centre.
For more information about the Rexdale Community Health Centre, please click here.
About Apotex
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceutical products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at www.apotex.com.
Media inquiries: Contact Apotex Media, [email protected]
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Sep 18, 2026
Apotex Health Corp. announces closing of upsized bought deal secondary offering
Toronto, Ontario, September 18, 2026 – Apotex Health Corp. ("Apotex" or the "Company") announced today the closing of the previously announced upsized secondary offering (the "Offering") of common shares of the Company (the "Common Shares") by an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders").
-
Sep 15, 2026
Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million
Toronto, Ontario, September 15, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that, as a result of strong demand, Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an amended agreement with the syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to increase the size of the previously announced bought deal secondary offering of common shares of the Company (the "Common Shares"). Under the amended agreement, the Underwriters have agreed to purchase 25,000,000 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $850,000,000 (the "Upsized Offering").
-
Sep 15, 2026
Apotex Health Corp. announces $750 million bought deal secondary offering
Toronto, Ontario, September 14, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an agreement with a syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to complete a secondary offering on a bought deal basis (the "Offering") of common shares of the Company (the "Common Shares"). Under the agreement, the Underwriters have agreed to purchase 22,058,825 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $750,000,050.